Eric Sagonowsky

Editor

Eric Sagonowsky is an editor with FiercePharma and FierceVaccines. He joined the Fierce staff in November 2014 and covers topics such as drug pricing, biosimilars and product liability litigation.

Stories by Eric Sagonowsky

Copay coupons help patients stick to drugs—but only a bit: study

by Eric Sagonowsky

Tuesday, January 15, 2019

Patients using copay coupons were more likely to stay on their drugs longer, but the vouchers didn't help with outcomes, a new study found.

Sen. Schumer curiously ties GSK Shingrix shortage to shutdown

by Eric Sagonowsky

Tuesday, January 15, 2019

GlaxoSmithKline has had a Shingrix shortage for months, but now Sen. Schumer said the government shutdown is making the situation worse.

Want to thrive, pharma? Forget 'me-too' drugs, CSL chief says

by Eric Sagonowsky

Monday, January 14, 2019

Pharma is too preoccupied with short-term growth, so it's going the easier me-too route rather than focusing on "transformative" therapies, the CEO said.

If Trump teams with Dems, pricing bills might actually pass: analyst

by Eric Sagonowsky

Monday, January 14, 2019

The Democrats' new drug pricing bills are "flawed"—and likely to fail—unless Trump crosses the aisle. And as one analyst sees it, he just might.

CEO told pharma to self-police pricing—then J&J hiked them

by Eric Sagonowsky

Friday, January 11, 2019

J&J's CEO said this week the pharma industry needs to police itself on pricing. Days later, his company raised prices on two dozen drugs.

Teva settles Medicaid fraud suit for $135M

by Eric Sagonowsky

Friday, January 11, 2019

Fourteen years after Illlinois' AG accused Teva of defrauding Medicaid with inflated pricing, the company has settled for $135 million.

Eli Lilly plots 250 job cuts in €100M manufacturing revamp

by Eric Sagonowsky

Thursday, January 10, 2019

Boehringer and Sanofi aren't the only ones chopping jobs in France. Now, Lilly says it's cutting 250 positions as it "modernizes" a Fegersheim plant.

Novartis reps use AI to give the right docs the info they want

by Eric Sagonowsky

Wednesday, January 9, 2019

Artificial intelligence is a big buzzword in R&D right now, but at Novartis, it's hard at work in the sales department, too.

Trump, angry at latest price hikes, calls White House meeting

by Eric Sagonowsky

Wednesday, January 9, 2019

The president called advisers for a special meeting on drug prices after a new round of hikes from many industry players, Politico reports.

Novavax's NanoFlu bests Sanofi's Fluzone HD in seniors

by Eric Sagonowsky

Wednesday, January 9, 2019

Novavax's NanoFlu vaccine beat Sanofi's Fluzone HD in seniors in a midstage test, setting up the smaller company's shot for a move into phase 3.